Contact urticaria is localized color changes and swelling on the skin that appear immediately after coming into contact with a specific substance. Contact urticaria can result from a variety of ...

In phase 3 trials, dupilumab significantly reduced itch and hives compared with placebo. The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult and ...

Phase 3 trials showed significant reductions in itch and urticaria severity with dupilumab compared to placebo at week 24. Dupilumab offers a new treatment option for CSU, being the first targeted ...

Dupilumab was approved for treatment of chronic spontaneous urticaria in patients aged 12 years and older. Several studies reported reduced itch severity and urticaria activity with dupilumab.

Key presentations on chronic spontaneous urticaria (CSU) at the American Academy of Dermatology 2025 include late-breaking data on the anti-c-Kit antibody briquilimab and positive results for ...

Patients with CSU face significant disease burden due to delayed diagnosis, inadequate symptom control, and mental health impacts, necessitating patient-centered care approaches. Despite ...

Dupixent is the first new targeted therapy to receive FDA-approval for chronic spontaneous urticaria in adults and adolescents over 12 years of age in over a decade. The FDA has approved Regeneron’s ...

One came in 2023, however, when the FDA rejected it as a treatment for chronic spontaneous urticaria (CSU), asking for more data. Eighteen months later—and backed by more conclusive results ...

Jeanni I. Wegener, age 74 of Colgate, WI passed away peacefully in her sleep March 28, 2025, at the Pavilion at Glacier Valley in Slinger, WI. Jeanni was born July 29, 1950, in Brown Deer ...

Dermatitis, scabies, acne vulgaris, viral skin diseases, and urticaria were the five skin conditions with the highest global age-standardized DALY rates in 2021. The age-standardized DALY rate for ...

Sanofi and Regeneron Pharmaceuticals drug Dupixent has won FDA approval for chronic spontaneous urticaria, introducing a new approach to the treatment of this inflammatory skin disorder.

Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and ...